You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

New Paradigms in HR-Positive Advanced Breast Cancer: What Have We Learned?

  • Authors: Martine Piccart, MD, PhD; Nicholas Turner, MA, MRCP, PhD
  • CPD Released: 6/22/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 6/22/2018
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor (HR)-positive advanced breast cancer.

The goal of this activity is to improve physician knowledge regarding treatment options for patients with HR-positive, HER2-negative, metastatic breast cancer.

Upon completion of this activity, participants will:

Have increased knowledge regarding the

  • Efficacy, safety, and tolerability data for agents that target cyclin-dependent kinase (CDK)4/6 in patients with advanced HR-positive advanced breast cancer

Have greater competence related to

  • Selection of first- and second-line therapy for HR-positive advanced breast cancer based on patient, disease, and clinical factors


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Martine Piccart, MD, PhD

    Professor of Medicine, Jules Bordet Institute, Université Libre de Bruxelles; Chair, Breast International Group (BIG AISBL), Brussels, Belgium

    Disclosures

    Disclosure: Martine Piccart, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca;MSD; Novartis; Odonate; Pfizer; Roche-Genentech; Crescendo Biologics; Periphagen; Huya; Debiopharm, PharmaMar
    Received grants for clinical research from: AstrZeneca; Lilly; MSD Novartis; Pfizer; Roche-Genentech; Synthon; Radius; Servier

  • Nicholas Turner, MA, MRCP, PhD

    Academic Consultant Medical Oncologist, Breast Cancer Now Research Centre, The Institute of Cancer Research, Breast Cancer Lead, Biomedical Research Centre, London, UK

    Disclosures

    Disclosure: Nicholas Turner, MA, MRCP, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
    Received grants for clinical research from: Pfizer Inc.; Roche

Editors

  • Deborah Middleton, MS

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

  • Anne M. Sendaydiego, PharmD

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

New Paradigms in HR-Positive Advanced Breast Cancer: What Have We Learned?

Authors: Martine Piccart, MD, PhD; Nicholas Turner, MA, MRCP, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 6/22/2017

Valid for credit through: 6/22/2018

processing....